

Index

- A**
- Abf2, 160
 - AD. *See* Alzheimer's disease
 - AFG3L2, 162
 - Africa swine fever virus (ASFV), 468
 - Aging
 - heat shock factors, 431
 - proteostasis network regulation, 450–452
 - Ago2, 335, 467
 - Aha1, 333, 335, 338–339, 504
 - AIRAP, 267
 - AIRAPL, 267–268
 - AKT, 274, 467
 - ALK, 503
 - ALMC2, 487
 - ALP. *See* Autophagy lysosome pathway
 - α -Synuclein, 375, 522
 - ALS. *See* Amyotrophic lateral sclerosis
 - Alzheimer's disease (AD), 186, 519
 - autophagy lysosomal pathway, 290–291
 - chaperone studies, 213–214, 216–217, 222
 - Hsp90 studies, 337
 - polyphosphate studies, 392, 394–395, 399
 - AMPK, 444
 - Amyloid
 - chaperone modulation
 - aggregation prevention, 217–222
 - degradation of amyloid-forming proteins, 225–227
 - disaggregation of amyloids, 223–225
 - fibril spreading, 227–229
 - neutralization/detoxification of aggregates, 222–223
 - overview, 216
 - prospects for study, 229
 - quality control, 216–217
 - characteristics, 42–44
 - formation kinetics and mechanisms, 44–47
 - functional amyloids
 - bacteria, 22–23
 - biofilms, 23–24
 - classification, 15–22
 - curli, 23–27
 - disease amyloid comparison, 32–34
 - HET-s, 22, 30–32
 - peptide hormones
 - aggregation in Golgi, 27–28
 - membrane formation, 28–29
 - release, 29–30
 - storage in Golgi, 28–29
 - neurodegenerative diseases, 214–216
 - overview of diseases, 13, 41–43
 - polyphosphate
 - amyloidogenic protein interactions, 393–395
 - cytotoxicity amelioration, 396–397
 - prospects for study, 52, 55
 - protein homeostasis context, 48–49
 - structure–activity relationship, 14–15
 - therapeutic intervention, 50–52
 - toxicity, 47–48
- Amyotrophic lateral sclerosis (ALS), 214, 262, 264, 290–291, 293, 404, 409, 524, 532
- ApoB, 135
- ASFV. *See* Africa swine fever virus
- ATAD1, 104
- ATF4, 79, 88, 182, 186, 189, 445–446
- ATF5, 182, 186, 189
- ATF6, 60, 62–64, 79, 445–446, 481–482, 484–489
- ATFS-1, 99, 180–181, 185, 188–189, 445–446
- Atg7, 293
- Atg32, 167
- ATM, 313
- ATR, 313
- Atropine, 501
- ATXN2, 524
- Autophagy lysosome pathway (ALP)
 - chaperone-mediated autophagy, 288–289
 - history of study, 285
 - macroautophagy, 287–288
 - microautophagy, 288
 - neurodegenerative disease, 290–294
 - proteostasis network, 289
 - therapeutic targeting, 294–295
- B**
- BAG1, 225–226
 - BAG2, 200
 - Bag2, 462
 - Bag3, 463
 - BAG4, 223
 - Bag6, 103
 - BAP, 466
 - BCR-ABL, 498, 501
 - β -Solenoid, 30
 - β -TRCP, 269
 - BiP, 63–64, 68–70, 79, 81–83, 99, 115, 118, 128–130, 132–133, 217, 221, 462, 466, 485
 - BIRC5, 467
 - BIX, 485
 - Blm10, 272

Index

- BMRF1, 463
BRICHOS domain proteins, 222
Brown adipose tissue, 444
- C**
- CaMKII, 276
CamSol
 aggregation-promoting hotspot identification, 6–7
 biophysical prediction of protein solubility, 3–6
 design of protein mutants with enhanced solubility, 7
 protein variant library screening, 6
 proteome-wide predictions of solubility, 9–11
 solubility profile
 intrinsic, 4
 structurally corrected profile, 4–6
 solubility score, 6
 stability versus solubility trade-offs, 7–9
CAP80, 468
Carboxypeptidase Y (CPY), 101, 107
CASA. *See* Chaperone-assisted selective autophagy
Casein kinase, 179
CBEP, 22
CCHFV. *See* Crimean-Congo hemorrhagic fever virus
CCT, 315, 445, 465–466
Cdc37, 331–332, 334–336, 339, 464, 467
Cdc48, 134, 267
Cdk4, 332
Ceapins, 488
CFTR, 135, 140–141, 338
Chaperone-assisted selective autophagy (CASA), 201, 227
Chaperone-mediated autophagy (CMA), 201, 288–289
Chikungunya virus, 470
CHIP, 441, 464, 505
CHMP2B, 294
CHOP, 88–90, 182, 189
Cis1, 105
CL1, 105
CLEAR, 287
CLEC-41, 449
ClpA, 373
ClpB, 373–374, 376–382, 384
ClpC, 373
ClpP, 160, 163, 373
ClpX, 373
CLPXp, 160, 162
CMA. *See* Chaperone-mediated autophagy
CMV. *See* Cytomegalovirus
CNPY3, 323
Cns1, 332
COX, 162
Cpr6, 333
Cpr7, 332
CPY. *See* Carboxypeptidase Y
Crimean-Congo hemorrhagic fever virus (CCHFV), 467
Crystallins. *See* HSPB4; HSPB5
CsgA, 24–26, 33, 393
CsgB, 24–25, 33
CsgC, 24
CsgD, 24
CsgE, 24
CsgF, 24
CsgG, 24, 27
CST, 312
Cue5, 271
Curli, 23–27
Cushing's disease, 339
Cyclin B, 274
Cyp40, 332, 338
Cytomegalovirus (CMV), 135, 463, 465
- D**
- DAF-16, 445, 449–450
DARS2, 160
Ddi1, 262
DDI2, 270
Ddx4, 408
Dengue virus, 462, 465–466, 470
DFCP1, 288
Diabetes, amyloid, 522, 536
DIABLO, 168
Djp1, 106
DnaJ, 86, 306–307, 462
DNAJA1, 224
DNAJA2, 224
DNAJB1, 223–224
DNAJB6, 221, 463
DNAJB8, 221
DNAJB11, 462
DNAJC5, 227
DNAJC6, 228
DNAJC13, 229
DNAJC14, 466
DNAJC19, 165
DnaK, 306–307, 422
Doa10, 101
DP1, 330
DP2, 330
DRP1, 163–164
DsbC, 123
DsbD, 123
Dsk2, 104, 262, 266–267
- E**
- EBV. *See* Epstein–Barr virus
Ecm29, 275
EDEM, 118–119, 130–131
EGFR, 504
eIF2, 88–90, 183
EnaC, 141
Endoplasmic reticulum (ER). *See also* Unfolded protein response
 protein folding, 59–60
 redox regulation
 calcium homeostasis, 120–122
 Erdj5 quality control, 118–120

oxidative folding, 115–118
prospects for study, 122–123
redox environment, 113–114

Endoplasmic reticulum–associated degradation (ERAD)
diseases, 135–140
overview, 60, 69, 484
prospects for study, 140–141
protein abundance regulation, 134–135
quality control, 118–120, 131–134
substrate recognition, 135

Epstein–Barr virus (EBV), 463, 467, 470

ER. *See* Endoplasmic reticulum

ERAD. *See* Endoplasmic reticulum–associated degradation

ERAL1, 160

Erdj4, 86

Erdj5, 114, 118–121, 130

ERK, 468, 504, 507

ERK1, 443

ERK2, 287

Ero1, 115–117

F

FapA, 27

FapB, 27

FapC, 23, 25–27, 33

FapE, 27

FapF, 27

FASD. *See* Fetal alcohol spectrum disorder

FBXW7, 269, 426, 443

Fetal alcohol spectrum disorder (FASD), 429

FGF21, 183, 185

FICD, 82–83

FK506. *See* Tacrolimus

FKBP8, 464

FKBP12, 290, 526

FKBP51, 332, 338–339

FKBP52, 332, 338–339

FLP-2, 183

FOXA, 445, 449

FOXO, 445, 449

FUNDC1, 168

FUS, 375, 406, 409–410, 412, 450, 532

G

GADD34, 88

GCN2, 186

GDF15, 184

Get3, 97

Glutathione, 114–115, 117, 121

Glutathione peroxidase, 115

GroEL, 308, 313–315, 468

GroES, 314, 468

Grp94, 130, 322–323, 326, 330, 496

Grp170, 462

GrpE, 307

GSK3 β , 443

H

HAC1, 62, 77, 79

HBV. *See* Hepatitis B virus

Hch1, 333

HCV. *See* Hepatitis C virus

HD. *See* Huntington's disease

HDAC3, 315

HDAC6, 223

HDAC7, 442

HDAC9, 442

Hdj1, 86, 442

Heat shock factors (HSFs). *See also specific factors*
functions
development, 428–430
metabolism, 430
interplay between factors, 427–428
overview, 422
pathology
cancer, 430–431
degeneration and aging, 431
posttranslational modifications, 425
promoter architecture, 427
prospects for study, 431–432
structure, 422–425

Hepatitis B virus (HBV), 464–467, 470

Hepatitis C virus (HCV), 462–463, 465, 469–470

HER2, 503

HERP, 133

Herpes simplex virus (HSV), 463, 470

HET-s, 22, 30–34

HIV. *See* Human immunodeficiency virus

HMG-CoA reductase, 134

hnRNPA1, 375

hnRNPA2, 375

HOP, 503, 505

Hop, 330, 333, 338

HPIV. *See* Human parainfluenza virus

HPV. *See* Human papillomavirus

HRD1, 268

Hrd1, 133

Hrd3, 133

HRI, 182

Hsc82, 322

HSF1
aging studies, 431
cancer studies, 511
developmental control and tissue-specific responses,
428–430, 444–445
heat shock response, stress resilience, and proteostasis,
441–444
Hsp70 interactions, 308
Hsp90 regulation, 329, 503
interaction with other heat shock factors, 427–428
metabolism function, 430
organismal level cell stress responses, 445–446
posttranslational regulation, 425–426
promoter, 427
structure, 422
virus replication cycle, 461

Index

- HSF2, 422, 425–431
HSF3, 422
HSF4, 422, 425, 427, 429–430
HSF5, 422
HSFs. *See* Heat shock factors
HSFs. *See* Heat shock factors
HSFX, 422
HSFY, 422
Hsj2, 463
HSP8A, 288
Hsp10, 178
Hsp26, 414
Hsp33, 414
Hsp40, 128–129, 133, 199, 240, 249
Hsp42, 414
Hsp47, 69
Hsp60, 178, 199, 313–315
Hsp70. *See also specific family members*
 amyloid detoxification, 223, 225–226
 endoplasmic reticulum–associated degradation, 128–129
 overview, 199–200, 216–217, 306–309
 ribosome interactions, 240, 247, 249
 virus replication cycle, 462, 465
Hsp78, 373
Hsp82, 322, 325
Hsp90
 chemical biology
 equilibrium and kinetic binding, 497–502
 essentiality studies, 502–505
 historical perspective, 497
 kinetic selectivity for cancer
 diagnostics, 505–508
 proteomics, 508–510
 prospects for study, 510–511
 clients
 binding site, 335–336
 overview, 334
 recognition and folding, 334–335
 cochaperones, 330–334
 diseases
 cancer, 336–337
 cochaperones, 338
 neurodegenerative disease, 337
 psychiatric disease, 337–338
 endoplasmic reticulum–associated degradation, 130, 135
 evolution and isoforms, 322–323
 history of study, 321–322
 inhibitors
 amino-terminal inhibitors, 338–339
 binding disruption, 339–340
 carboxy-terminal inhibitors, 339
 overview, 199, 309–313
 prospects for study, 340
 protein quality control, 217
 regulation, 329–330
 structure of cytosolic form, 323–326
 virus replication cycle, 462–464
Hsp104, disaggregation mechanism plasticity, 383–384
Hsp105
 overview, 106, 200, 374–376, 462
 substrate engagement and release, 380–383
 substrate translocation, 376–380
Hsp110, 135, 200, 217, 226, 224–225, 374
HSPA5. *See* BiP
HSPA8, 223–228
HSPB1, 222, 354, 356, 358–364, 467–468
HSPB2, 356–357, 360
HSPB3, 356–357, 360
HSPB4, 353–354, 356, 360–362, 364
HSPB5, 222
HSPB5, 353–354, 356, 358–363
HSPB6, 354, 357–358
HSPB7, 360
HSPB8, 354, 360
HSV. *See* Herpes simplex virus
HTLV. *See* Human T-lymphotropic virus
HtpG, 326
HtrA1, 375
Hul5, 274–275
Human immunodeficiency virus (HIV), 375, 463, 467, 470
Human papillomavirus (HPV), 463
Human parainfluenza virus (HPIV), 464
Human T-lymphotropic virus (HTLV), 467
Huntington's disease (HD), 213, 450, 530
HYOU1, 462
HypF-N, 222
- I**
- IAPP, 522
IKK, 467
IMMP2, 158
IRE1
 BiP interactions, 68–69, 84–87
 chaperone interactions, 69, 85–87
 direct activation by unfolded proteins, 83–85
 HFS1 integrated response, 445–446
 membrane signaling, 63
 prospects for study, 70–71
 stress-sensing models, 63–68
 translation repression, 87–90
 translocon interactions and oligomerization, 69–70
 unfolded protein response-sensing overview, 60–63, 77, 484–485, 488
- J**
- Japanese encephalitis virus (JEV), 462–463, 470
JEV. *See* Japanese encephalitis virus
JMJD-1.2, 182
JMJD-3.1, 182
Kaposi's sarcoma–associated herpesvirus (KSHV), 463, 467, 470
KEAP-1, 446
KSHV. *See* Kaposi's sarcoma–associated herpesvirus

- L**
- LACTB, 167
 - LAF-1, 408
 - LAMP1, 287
 - LAMP2A, 201, 226, 287–288
 - LC4, 288
 - LDLR, 119–120
 - LIN-65, 182
 - Localization, protein
 - degenerate signal recognition, 96–99
 - diseases, 106–107
 - impaired organelle import, 99–101
 - monitors of mislocalization
 - cytosolic monitors, 101–104
 - membrane monitors, 104–106
 - overview, 95–96
 - Lon, 159–160, 162–163
 - LONP1, 180, 183
 - Low-complexity regions. *See* Phase separation, proteins
 - LRPPRC1, 160
 - Lysosome. *See also* Autophagy lysosome pathway
 - overview, 285–287
- M**
- Major basic protein (MBP), 22, 29
 - MAP1, 252
 - MARCH6, 105
 - MBP. *See* Major basic protein
 - MCU, 162
 - MEK, 442
 - MET-2, 182
 - MFE, 163
 - Mgr2, 159
 - MiD49, 163
 - MiD51, 163
 - MIPER*, 158
 - mIR-122, 467
 - MiT, 287
 - Mitochondria
 - biogenesis, 178
 - protein import, 178–179
 - Mitochondrial-processing peptidase (MPP), 166, 178
 - Mitochondrial proteolysis
 - lipid metabolism regulation, 165–167
 - metabolism regulation
 - inner membrane dynamics, 164–165
 - outer membrane dynamics, 163–164
 - mitophagy, 167–168
 - proteome organization role, 158–159
 - respiration control
 - genome maintenance and gene expression, 159–160
 - OXPPOS complex assembly and activity, 162–163
 - protein synthesis, 160–162
 - Mitochondrial unfolded protein response (UPR^{mt})
 - activation effects on transcription
 - cell-autonomous regulation, 183–184
 - chromatin remodeling in activation, 181–182
 - integrated stress response, 182
 - metabolic adaptations, 180
 - mitochondria network recovery and function, 180
 - nuclear communication, 180–181
 - translation regulation in mitochondria, 183
 - diseases
 - cancer, 186
 - infection, 186–187
 - mitochondrial diseases, 185–186
 - neurodegenerative diseases, 186
 - longevity studies, 184–185
 - prospects for study, 188–189
 - regulation
 - activation, 179–180
 - overview, 179
 - signaling of deleterious mitochondrial genome, 185
- Mitofusin, 163
- MLKL, 32
- MPP. *See* Mitochondrial-processing peptidase
- MPP11, 251
- Mrp132, 160, 162
- MRPP1, 183
- MRPP2, 183
- MRPP3, 183
- Msp1, 104–105
- mTOR, 271, 290, 294
- mTORC1, 185–186, 287, 290, 444
- MutL, 323
- MYC, 505, 511
- N**
- NBN, 313
 - NBR1, 288
 - NEDD4, 426
 - NFE2L1, 446
 - NFE2L2, 446
 - NF- κ B, 467
 - NMNAT2, 375
 - NOTCH, 427, 505, 511
 - Npl4, 134
 - NRF1, 268–270, 446
 - NRF2, 330, 388, 445–446
 - NS5A, 464
 - NS5B, 464
 - NVP-AUY922, 498
- O**
- Oct1, 166
 - OMA1, 165, 168
 - Oma1, 167
 - OPA1, 164–165
 - OPTN, 288
 - Orb2, 33
- P**
- p23, 465
 - p53, 334, 336–338
 - P73, 468
 - P300, 442

Index

- Pab1, 411–412
Paclitaxel, 507
PAN, 26
Parkinson's disease (PD)
 chaperone studies, 213–214, 216–217, 228
 genetic screens, 524
 polyphosphate studies, 392, 395, 397
PARL, 167–168
PARP1, 308
PCNA, 266
PD. *See* Parkinson's disease
PDI. *See* Protein disulfide isomerase
PDIA1, 462, 487–488
PDIA3, 462, 488
PDIA4, 487–488
PDIA6, 69, 487–488
PDK2, 167
Pdr1, 268
PDR3, 188
Pdr3, 99, 268
Peptidyl-prolyl isomerase (PPI), 90, 130
PERK, 60, 62–64, 66–68, 70, 83, 85, 87–88,
 90, 182, 186, 446, 484, 488
Peroxiredoxin, 115
Pex5, 96
Pex15, 104
PGAM5, 168
PGC-1 α , 287, 430, 444
PHA-4, 445, 449, 451
Phase separation, proteins
 factors affecting solubility and phase behavior
 extrinsic factors, 406–407
 intrinsic factors, 405–406
 low-complexity regions
 prions, 408–410
 protein folding, 413–414
 regulation of phase separation and phase behavior,
 407–408, 410–411
 stressed cell studies, 411–413
 overview, 403–405
PINK1, 99, 167–168, 188
Pinocytosis, 288
PISD, 167
PKA. *See* Protein kinase A
PKR, 182, 186
Pmel17, 33
PML-SYK, 507
PMPCA, 158
PMPCB, 158
PN. *See* Proteostasis network
Polyphosphate
 amyloid cytotoxicity amelioration, 396–397
 brain
 functions
 channels and pores, 395–396
 neurotransmission, 396
 levels and regulation, 395
 overview, 391–392
 prospects for study, 397–399
 protein interactions
 amyloidogenic proteins, 393–395
 nonamyloidogenic proteins, 392–393
PPI, 90
PP5, 330–332, 339
PPAR α , 287
PPI. *See* Peptidyl-prolyl isomerase
PPI464
PPIR15B, 88
PPX, 396–397
PQM-1, 449
PRELID1, 166
Proteasome
 assembly, 260–261
 conformational states, 263–264
 levels and regulation
 NRF1, 268–170
 posttranslational regulation, 271–272
 Rpn4, 268
 overview, 259–260
 phosphorylative regulation, 275–276
 Rpn6 function, 270–271
 substrate recognition and ubiquitin code, 264–268
 tomographic resolution of states within cells, 264
 ubiquitin. *See* Ubiquitin
 USP14 regulation, 272–274
Protein disulfide isomerase (PDI), 60, 114–118,
 121–122, 130, 135
Protein kinase A (PKA), 159, 179
Protein solubility
 aggregation and biophysical prediction, 3
 overview, 1–3
 prediction. *See* CamSol
Proteostasis network (PN)
 aging and heat shock response, 450–452
 cell differentiation role, 203–205
 cell-nonautonomous regulation, 446–450
 degradation of proteins, 201
 developmental control, 444–445
 folding and conformational maintenance, 197–200
 functional modules, 195–196
 organization, 196–197
 overview, 440–441
 proteinopathy amelioration, 205
 stress-response pathways, 202–203
 synthesis of proteins, 197
Proteotoxicity mapping
 driver-responder architecture, 528, 530–531
 genetic screens, 522, 524–525
 missing proteinopathy identification, 527–528
 overview, 521–522
 prospects, 535–536
 proteomics, 526
 ResponseNet, 526–527
 transcriptomics, 525–526
Psd1, 166–167
PU24FCl, 500
Pub1, 411–412
PU-H71, 498–499, 502, 505–510

- R**
- RAB5, 287
 - RAB7, 287
 - Rabies virus, 464–465, 467
 - Rad23, 134, 262, 266–267
 - ResponseNet, 526–527
 - Ribosome
 - functional features, 240–242
 - nascent polypeptide-associated complex, 244–247, 252–253
 - ribosome-associated complex, 247–252
 - trigger factor, 239, 242–244
 - RIP1, 32
 - RIP3, 32
 - RNA polymerase II, 463
 - RNF126, 103
 - ROMO1, 159
 - Rpd3, 315
 - Rpn1, 266
 - Rpn4, 268
 - Rpn6, 270–271, 275
 - Rpn10, 275
 - Rpn11, 262–264, 272, 274
 - Rpn13, 266, 275
 - Rpt2, 264
 - Rpt3, 264
 - Rpt5, 264
 - RPT6, 276
 - RTP1, 70
 - RuBisCO, 313
 - Rvb1, 332
- R**
- SAHA, 141
 - San1, 101
 - Sba1, 333–334
 - Scopalamine, 501
 - Sec61, 128, 130, 133, 245–246
 - SEN2, 164
 - SEN3, 164
 - SEPN1, 121
 - SERCA, 485
 - SERCA2b, 120–122
 - Set3, 315
 - Sgt1, 332, 334
 - SGT1, 462
 - Sgt2, 106
 - SGTA, 103, 462
 - sHSPs. *See* Small heat shock proteins
 - σ^{32} , 307
 - Signal recognition particle (SRP), 96–98, 101, 128, 246, 251–252
 - Sil1, 130
 - SIL1, 466
 - SIRT1, 442, 444, 451
 - SKN-1, 445–446, 451
 - Smac, 168
 - Small heat shock proteins (sHSPs). *See also specific proteins*
 - activation mechanisms
 - metals, 362–363
 - oxidative stress, 362
 - pH, 361–362
 - phosphorylation, 363
 - thermal, 361
 - client interactions
 - mechanisms, 363–365
 - structure, 358–359
 - constitutive function, 360
 - overview, 353–354
 - prospects for study, 365–366
 - structure, 354–358
 - SMYD3, 312
 - SNX-2112, 498
 - SOD1, 293, 450
 - Solubility. *See* Protein solubility
 - Spg5, 272
 - SPG7, 162
 - SRP. *See* Signal recognition particle
 - SRP54, 96–97, 103
 - Ssa1, 101
 - Ssb, 247, 250–251, 253
 - Ssb1, 250
 - Ssb2, 250
 - Ssl2, 313
 - Ssz1, 249–250, 252
 - STARD1, 166
 - STARD7, 166, 168
 - START, 166
 - STAT5, 507
 - Sti1, 330
 - Stress granule, 409–411
 - SUMO, 266
 - Sup35, 22, 380, 408, 412–413
 - SV40, 462, 468
 - SV5, 465
 - SWI/SNF, 315
 - SWR1, 315
- T**
- Tacrolimus (FK506), 332, 526
 - TAF15, 375
 - TAF5, 315
 - TAg, 468
 - TAK1, 468
 - Tau, 394
 - TBK1, 288
 - TCP1, 313, 315
 - TDP-43, 375, 409, 522, 524, 532
 - TF. *See* Trigger factor
 - TFAM, 159–160
 - TFE3, 287
 - TFEB, 287
 - TFIID, 315
 - Tim9, 159
 - Tim10, 159
 - TIM23, 178–179

Index

- TIMM17A, 159
TIMM23, 159
Tiotropium, 501
TMX2, 525
TNF- α , 467
TPR1, 330
TPR2A, 330
TPR2B, 330
TransposeNet, 528–529
Transthyretin (TTR), 140, 217, 221, 228, 519
TRAP1, 322–323, 326, 329, 330, 496
TRC8, 105
TRC35, 103
TRC40, 103
TRIAP1, 166
TriC, 199, 203–204, 223, 250, 313, 445, 465–466, 480
Trigger factor (TF), 239, 242–244, 246, 252–253
TRIM11, 274
TRPA1, 396
TRPML1, 289
Tsc1, 333
Tsc2, 333
TTR. *See* Transthyretin
TXNDC5, 487
- U**
- UBE2O, 104, 205
UBE3C, 274–275
Ubiquilin, 107
Ubiquilin2, 262, 267
Ubiquitin
 conjugation, 274–275
 proteasome recognition and processing, 261–263
 substrate recognition and ubiquitin code, 264–268
Ubl4A, 103
Ubp6, 263, 272–273
Ubr1, 101
Ubr2, 101
UCH37, 263
UCHL5, 263
Ufd1, 134
Ufd2, 267
UL9, 308, 463
UL14, 468
UL40, 463
UmuC, 308
Unfolded protein response (UPR)
 ATF6 arm, 481–482, 485–486
 chaperone availability regulation by posttranslational
 modifications, 79–83
 early steps in activation, 83
 endoplasmic reticulum membrane health monitoring, 70
 mitochondria. *See* Mitochondrial unfolded protein
 response
 overview, 77–79
 prospects for study, 70–71
 protein-folding capacity, 60–63
 signaling, 63
 stress sensing
 BiP–IRE1 interactions, 68–69
 direct activation models, 64–65
 early models, 63–64
 recognition of unfolded proteins, 66–68
 translation repression, 87–90
UPR. *See* Unfolded protein response
UPR^{mt}. *See* Mitochondrial unfolded protein response
Usa1, 133
USP14, 263, 272–275
USP19, 227
USP30, 167
UvrA, 308
- V**
- Vesicular stomatitis virus (VSV), 464–465, 467
Virus infection, chaperone interplay
 antiapoptotic signaling, 467
 evolutionary aspects, 468–469
 overview, 459–462
 replication roles
 disassembly, 462
 entry, 462
 extracellular chaperones, 467
 folding and assembly, 463–467
 nuclear import, 462–463
 regulated transition to replication, 465
 therapeutic targeting of chaperones, 469–470
 virus chaperone-like folding, 468
VP16, 468
Vpr, 463
VPS41, 524
Vpx, 463
VSV. *See* Vesicular stomatitis virus
- W**
- WIPI-1, 288
WIPI-2, 288
- X**
- XBP1, 62, 71, 79, 445–446, 448–449, 485–486
XRCC1, 308, 313
- Y**
- YCK3, 524
Ydj1, 101
Yellow fever virus (YFV), 466–467, 470
YFV. *See* Yellow fever virus
Yme1, 167
YME1L, 159, 165, 167, 178
- Z**
- ZFAND1, 267
ZFAND5, 267–268
Zika virus, 467, 470
Zuo1, 251